Patents Assigned to Resistentia Pharmaceuticals AB
  • Immunogenic polypeptides for inducing anti-self IgE responses
    Patent number: 7459158
    Abstract: The invention relates to methods and materials involved in the treatment and prevention of various diseases such as infections and IgE-related diseases. Specifically, the invention relates to methods and materials that can be used to vaccinate a mammal against specific self or non-self antigens. For example, the methods and materials described herein can be used to reduce the effects of IgE antibodies within a mammal by reducing the amount of total and receptor bound IgE antibodies in the mammal. In addition, the invention provides vaccine conjugates, immunogenic polypeptides, nucleic acid molecules that encode immunogenic polypeptides, host cells containing the nucleic acid molecules that encode immunogenic polypeptides, and methods for making vaccine conjugates and immunogenic polypeptides as well as nucleic acid molecules that encode immunogenic polypeptides. Further, the invention provides an IgE vaccine that induces an anti-self IgE response in a mammal.
    Type: Grant
    Filed: June 19, 2002
    Date of Patent: December 2, 2008
    Assignee: Resistentia Pharmaceuticals AB
    Inventor: Lars T. Hellman
  • Methods and materials for treating inflammatory conditions
    Patent number: 7361742
    Abstract: The invention provides methods and materials for treating inflammatory conditions. Specifically, the invention provides polypeptides, isolated nucleic acids, host cells, and methods that can be used to induce an antibody response in a mammal against an antigen such as C5 or C5a. For example, the methods and materials described herein can be used to reduce the effects of C5a within a mammal by reducing the amount of total and receptor bound C5a in the mammal.
    Type: Grant
    Filed: December 1, 2003
    Date of Patent: April 22, 2008
    Assignee: Resistentia Pharmaceuticals AB
    Inventors: Rikard Holmdahl, Lars T. Hellman
  • Chimeric IgE polypeptides and host cells
    Patent number: 7232898
    Abstract: The invention provides methods and materials related to expressing chimeric IgE proteins. Specifically, the invention provides nucleic acid vectors, host cells, and methods for producing chimeric IgE polypeptides.
    Type: Grant
    Filed: May 15, 2003
    Date of Patent: June 19, 2007
    Assignee: Resistentia Pharmaceuticals AB
    Inventors: Mats Lundgren, Alexis Fuentes, Ann-Christin Magnusson
  • Immunogenic polypeptides for inducing anti-self IgE responses
    Patent number: 6913749
    Abstract: The invention relates to methods and materials involved in the treatment and prevention of various diseases such as infections and IgE-related diseases. Specifically, the invention relates to methods and materials that can be used to vaccinate a mammal against specific self or non-self antigens. For example, the methods and materials described herein can be used to reduce the effects of IgE antibodies within a mammal by reducing the amount of total and receptor bound IgE antibodies in the mammal. In addition, the invention provides vaccine conjugates, immunogenic polypeptides, nucleic acid molecules that encode immunogenic polypeptides, host cells containing the nucleic acid molecules that encode immunogenic polypeptides, and methods for making vaccine conjugates and immunogenic polypeptides as well as nucleic acid molecules that encode immunogenic polypeptides. Further, the invention provides an IgE vaccine that induces an anti-self IgE response in a mammal.
    Type: Grant
    Filed: September 22, 1999
    Date of Patent: July 5, 2005
    Assignee: Resistentia Pharmaceuticals AB
    Inventor: Lars T. Hellman